Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,303.00
Bid: 1,293.00
Ask: 1,297.00
Change: -15.00 (-1.14%)
Spread: 4.00 (0.309%)
Open: 1,312.00
High: 1,318.00
Low: 1,298.00
Prev. Close: 1,318.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
12th Apr 202111:00 amRNSNotice of Results
1st Apr 202110:00 amRNSTotal Voting Rights
31st Mar 20212:50 pmRNSAnnual Report and Notice of Annual General Meeting
24th Mar 20217:00 amRNSBoard Appointments & Succession Plan Announced
9th Mar 20212:00 pmRNSDirector/PDMR Shareholding
2nd Mar 20211:00 pmRNSDirector/PDMR Shareholding
1st Mar 20218:00 amRNSTotal Voting Rights
18th Feb 20217:00 amRNSFinal Results
4th Feb 20211:55 pmRNSNotice of Results
3rd Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20218:00 amRNSTotal Voting Rights
29th Jan 20214:58 pmRNSHolding(s) in Company
25th Jan 20215:14 pmRNSIndivior Reaches Settlement with Reckitt Benckiser
25th Jan 20218:00 amRNSHolding(s) in Company
20th Jan 20217:00 amRNSHolding(s) in Company
15th Jan 20213:04 pmRNSHolding(s) in Company
15th Jan 20217:00 amRNSIndivior Provides Preliminary FY 2020 Results
11th Jan 20211:00 pmRNSDirectorate Change
4th Jan 202110:29 amRNSTotal Voting Rights
4th Dec 202012:30 pmRNSDirector/PDMR Shareholding
4th Dec 20209:21 amRNSHolding(s) in Company
2nd Dec 20205:13 pmRNSHolding(s) in Company
30th Nov 20207:00 amRNSFurther statement re claim filed by RB
27th Nov 202011:24 amRNSClaim filed by Reckitt Benckiser Group - Amendment
27th Nov 202010:44 amRNSClaim filed by Reckitt Benckiser Group plc
24th Nov 20209:30 amRNSHolding(s) in Company
20th Nov 202011:30 amRNSAppointment of Chief Financial Officer
19th Nov 20207:00 amRNSAppointment of Non-Executive Chair
13th Nov 20207:00 amRNSCourt Approves Agreement with Justice Department
10th Nov 20207:00 amRNSIndivior to Participate in Upcoming Conferences
9th Nov 20208:48 amRNSBlock listing Interim Review
6th Nov 20202:24 pmRNSDirector/PDMR Shareholding
3rd Nov 20204:45 pmRNSHolding(s) in Company
29th Oct 202011:00 amRNS3rd Quarter Results
23rd Oct 20207:00 amRNSStatement re US Court Sentencing of Former CEO
15th Oct 20207:00 amRNSNotice of Results
6th Oct 20209:10 amRNSHolding(s) in Company
5th Oct 20202:41 pmRNSHolding(s) in Company
1st Oct 20209:11 amRNSTotal Voting Rights
24th Sep 20207:00 amRNSStrategic Alignment Actions Announced
4th Sep 20205:31 pmRNSDirectorate Change
1st Sep 20208:00 amRNSHolding(s) in Company
18th Aug 20204:09 pmRNSHolding(s) in Company
10th Aug 20209:15 amRNSHolding(s) in Company
5th Aug 20208:00 amRNSHolding(s) in Company
3rd Aug 20207:18 amRNSTotal Voting Rights
30th Jul 20207:12 amRNSHalf-year Report
27th Jul 20204:00 pmRNSBoard Committee Change
27th Jul 202011:21 amRNSAdditional Listing
24th Jul 20203:24 pmRNSAgreement with US Department of Justice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.